The need for new treatments for the neglected tropical diseases African sleeping sickness, Chagas disease and Leishmaniasis remains urgent with the diseases widespread in tropical regions, affecting the world's very poorest. We have previously reported bis-tetrahydropyran 1,4-triazole analogues designed as mimics of the annonaceous acetogenin natural product chamuvarinin, which maintained trypanocidal activity. Building upon these studies, we here report related triazole compounds with pendant heterocycles, mimicking the original butenolide of the natural product. Analogues were active against T. brucei, with a nitrofuran compound displaying nanomolar trypanocidal activity. Several analogues also showed strong activity against T. cruzi and L. major. Importantly, select compounds gave excellent selectivity over mammalian cells with a furan-based analogue highly selective while remaining active against all three cell lines, thus representing a potential lead for a new broad spectrum kinetoplastid inhibitor. O OBn Ar This paper Previous lead compound Butenolide addition Building on 6 13 R 1 = OH, R 2 = Bn 14 R = OBn, R 2 = Bn 15 R 1 = OH, R 2 = H 16 R = NH 2 , R 2 = Bn
Introduction
As defined by the World Health Organization, a neglected tropical disease (NTD) is a tropical infection that affects millions of people worldwide 1 but has seen inadequate investigation into treatment. 2, 3 This is principally due to the limited financial incentive in treating such conditions, which is linked to their prevalence in developing countries where healthcare spending is low and health infrastructure is poor.
Three such diseases are African sleeping sickness, 4 Chagas disease 5 and Leishmaniasis, 6 spread by the related kinetoplastid parasitic causative agents Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, respectively. These parasites are present in tropical regions across the world; T. brucei in sub-Saharan Africa, T. cruzi in South America and increasingly in North America 7 and Leishmania throughout the tropics and sub-tropics. 8 All three diseases share a genetic similarity and treatments developed for one specific disease have sometimes proved effective in treating another e.g. nifurtimox was originally developed for Chagas disease but has subsequently found application as a combination therapy for African sleeping sickness. 9, 10 The tropical plants of the Annonaceae species have long been known for their therapeutic properties, with the crude extracts of fruits, leaves, roots and bark used in traditional medicinal practices to treat a range of tropical diseases. 11 Interest in this plant species as a source of potential new drugs intensified with the discovery of a family of fatty acid derived natural products, collectively termed the Annonaceous acetogenins, which now number in excess of 400. 12 Structurally, the acetogenins are C32/C34 fatty acids generally characterised by a central array of one to three tetrahydrofuran (THF) rings with flanking hydroxyl groups and appended with a terminal butenolide ring system as found in squamocin 1 and senegalene 2 (Figure 1 ). 13 In contrast the tetrahydropyran (THP) ring system is less common and only seven acetogenins bear this motif including chamuvarinin 3. Members of this family of secondary metabolites are often highly cytotoxic displaying sub-nanomolar activity towards human cancer cell lines. 14 
Figure 1 Annonaceous acetogenins with known anti-kinetoplastid activity
By contrast, the biological evaluation of acetogenins for the treatment of NTD has thus far been remarkably limited considering the wide scale use across sub-Saharan Africa of acetogenin-containing crude plant extracts to treat African sleeping sickness. 15 Studies to date have primarily focussed on the phytochemical study of extracts from Annonaceae species for trypanocidal activity, with efforts focused on T. brucei, 16 though select compounds such as squamocin 1 have shown encouraging preliminary activity against T. cruzi and Leishmania strains. 17 In 2003 Laurens et al. reported that the root and bark extracts of Uvaria chamae are active towards T. brucei, which subsequently led to the isolation of chamuvarinin 3. 18 Chamuvarinin is one of only seven acetogenins to contain a tetrahydropyran ring system and the only acetogenin to contain an all adjacently linked bis-THF-THP core ether ring system.
In 2011, we reported the first total synthesis of chamuvarinin thereby establishing its absolute stereochemical structure. In addition our synthetic material displayed single figure micromolar activity towards the bloodstream form of T. brucei We built on these studies by designing a series of analogues inspired by chamuvarinin 3 that maintained T. brucei activity commensurate to that of the natural product ( Figure 2 ). 20 These analogues simplified the structure of chamuvarinin principally by replacing the central THF ring of the tricyclic core with a 1,4-triazole. This allowed rapid assembly of enantiomerically enriched THP building blocks via click chemistry, producing initial lead 4, which displayed low (1.8 µM) trypanocidal activity against bloodstream form T. brucei. From this starting point, other features of the natural product were introduced, in particular the pendant butenolide, the orientation of which ('left-or right-hand side' as drawn) was critical to activity with 6 maintaining activity, while 5 was completely inactive. These results encouraged us to explore alternatives to the butenolide, principally on the azide, or 'left-hand side' of the molecule. Inspired by the work of Yamashita and co-workers, we have focused on simple aromatic heterocycles that were found to act as effective butenolide mimics. 21 Our phenotypic screening program has now expanded to the other NTD parasite cell lines, T. cruzi and Leishmania major, so new potential inhibitors were evaluated against all three protozoa. 22 
Results and Discussion

Synthesis
In order to rapidly access analogues with varying head groups, we targeted a THP precursor with an extended chain already present. Beginning from alcohol 7, mesylation followed by S N 2 reaction with 6-((triisopropylsilyl)oxy)hexan-1-ol generated alkene 8 (Scheme 1). 23 After racemic epoxidation, kinetic resolution with Jacobsen salen catalyst produced chiral epoxide 9 with 95% ee. 24 Ring-opening with homoallyl magnesium bromide followed by epoxidation of the resulting double bond and in situ cyclisation generated THP alcohol 10 along with its diastereomeric pair (not shown) which were readily separated chromatographically. After conversion of the alcohol to azide 11 with DPPA, a "click" reaction with alkyne 12 generated the key THP-triazole-THP tricyclic core. Straightforward acidic deprotection then gave alcohol 13. Scheme 1 Synthesis of starting material: a) MsCl, NEt 3 , CH 2 Cl 2 , 0 °C → RT; b) NaH, 6-((triisopropylsilyl)oxy)hexan-1-ol, THF, reflux, 91% (2 steps); c) 3-chloroperbenzoic acid, CH 2 Cl 2 , 0 °C → RT, 83%; d) 0.6 mol% (S,S)-Co-salen catalyst, 6 mol% AcOH, H 2 O, THF, 49%; e) CH 2 CHCH 2 CH 2 MgBr, CuI, THF, -40 °C → RT, 84%; f) 3-chloroperbenzoic acid, CH 2 Cl 2 , 0 °C → RT; then (±)-camphorsulfonic acid (20 mol%), RT, 43% syn, 38% anti; g) diphenylphosphoryl azide, K 2 In an effort to separate the influence of the head group from that of the tricyclic core, a selection of heterocycles with simple alkyl chains were synthesised as controls (Scheme 3 
Biological Testing
We began our biological screening by testing relevant synthetic intermediates and compounds without head groups to give a baseline for activity ( Table 1 ). All analogues were screened against our kinetoplastid cell lines: T. brucei, T. cruzi and L. major as well as the human HeLa cell line which we used to assess potential selectivity of our analogues over mammalian cells. 25 All analogues were active at low micromolar concentrations in T. brucei, with the exception of diol 15, 26 With selectivity a primary concern, an initial set of our amide analogues was screened against the same cell lines ( Table 2) . Select compounds were also screened against the Vero cell line as a secondary, non- 18 showing no activity against both of these mammalian cell lines. The broad-spectrum anti-parasitic activity and selectivity of 18 was highly encouraging and led us to explore additional furan head groups below. 27 Table 2 Initial set of inhibitors 17-27 (*Toxicity likely due to biophysical effect, rather than on-target interaction)
We next curated a series of analogues in order to probe both steric and electronic variation of the pendant furan (Table 3 ). In T. brucei, methyl substitution (entries 2-4) was tolerated across the furan ring without loss of activity, as was a moderately electron withdrawing chloride group (entry 5).
Introduction of a nitro group in 32 led to a step-change improvement in activity, down to 37.3 nM (entry 6). By contrast, in T. cruzi any perturbation of the furan was detrimental to activity with all analogues greater than 100 µM, the only exception being nitro compound 32 with slightly improved activity (entry 6). For L. major, 5-methyl and 5-nitro substitution was tolerated (entries 2 and 6) but changing the substitution position or adding electron-withdrawing groups gave reduced activity (entries 3-5). The compounds showed generally moderate to no activity against HeLa with nitro compound 32 once again the exception at 0.38 µM. 32 was also examined in Vero with an EC 50 of 4.5 µM.
Although the results for 32 are encouraging, particularly the excellent activity in T. brucei, it should be noted that 5-nitroheterocycles are well known to have activity against T. brucei and T. cruzi and thus we were conscious the increased activity of 32 may result from the nitrofuran head group, with the tricyclic core possibly only helping in cellular localisation. 3, 28 We thus accessed pyrazole 33, furan 34 and nitrofuran 35 that contain a head group and a simple alkyl chain only to aid solubility. We were pleased to see that 33 and 34 were essentially inactive in all lines tested-indicating the primacy of the tricyclic core in these analogues (entries 7 and 8). As expected, nitrofuran 35 showed activity in all cell lines, with the results in T. cruzi, L. major and HeLa broadly in line with those of 32 (compare entries 6 and 8).
However, although activity was sub-micromolar in T. brucei, this nonetheless represents an almost a 20fold reduction in activity from 32 to 35, suggesting a synergistic effect between the tricyclic core of 32 and the nitrofuran head group. The exact nature of this effect remains under investigation. Table 3 Furan based inhibitors 18, 28-35 (*Toxicity likely due to biophysical effect, rather than on-target interaction)
Conclusion
In summary, we have accessed a new series based upon the previously established THP-triazole-THP motif incorporating a series of heterocycles in a position to mimic the butenolide core of our original natural product inspiration, chamuvarinin. These analogues displayed significant activity in a range of focused on further SAR studies of these key compounds, including expansion into the other heterocyclic linker series currently under investigation within our team.
Experimental
Chemistry
Synthetic details for tested compounds are described below. For details of the synthesis of intermediates, see Supporting Information.
General procedure for amide coupling
The appropriate carboxylic acid (34.2 µmol, 2 eq), EDCI.HCl (5.30 mg, 34.2 µmol, 2 eq) and DMAP 
Compounds
6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexan-1-ol 13
To a solution of 4-
2.18 mmol) in methanol (15 mL) and CH 2 Cl 2 (15 mL) was added a solution of (±)-CSA (101 mg, 0.440 mmol) in methanol (5 mL) and the mixture stirred at RT for 48 h. Reaction was quenched by the addition of saturated aqueous NaHCO 3 (30 mL). The mixture was extracted with CH 2 Cl 2 (3 x 30 mL) and the combined organic extracts washed with brine, dried (MgSO 4 ), filtered and concentrated in vacuo.
Purification by flash column chromatography (60% EtOAc/Hexane) provided alcohol 13 (1.12 g, 88%), as a colourless oil. 
4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1-(((2S,6S)-6-(4-((6-(benzyloxy)hexyl)oxy)butyl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazole 14
To a solution of sodium hydride (6.00 mg of 60% dispersion in mineral oil, 151 µmol) in dry THF (2ml) at RT was added benzyl alcohol (15.6 µL, 151 µmol). After 15 min, a solution of 6-(4-((2S,6S)-6-((4- N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
4.2.5
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)benzamide 17
The general procedure was followed using benzoic acid (4.20 mg, 34. 6 N-(6-(4-((2S,6S)-6-((4-((2S,6S) 
-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)furan-2-carboxamide 18
The general procedure was followed at a different scale. 7 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiophene-2-carboxamide 19
The general procedure was followed using thiophene-2-carboxylic acid (4.40 mg, 34.2 µmol).
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 19 (10.0 mg, 84%), as a colourless oil. 
N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1H-pyrrole-2-carboxamide 20
The general procedure was followed using pyrrole-2-carboxylic acid ( N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
4.2.9
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1-methyl-1H-pyrrole-2-carboxamide 21
The general procedure was followed using 1-methyl-2-pyrrolecarboxylic acid (4.30 mg, 34.2 µmol).
Purification by flash column chromatography (55% EtOAc/Hexane) provided amide 21 (9.0 mg, 76%), as a colourless oil. 10 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)furan-3-carboxamide 22
The general procedure was followed using furan-3-carboxylic acid ( N-(6-(4-((2S,6S)-6-((4-((2S,6S) 
4.2.11
-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiophene-3-carboxamide 23
The general procedure was followed using thiophene-3-carboxylic acid (4.40 mg, 34.2 µmol).
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 23 (11.0 mg, 92%), as a colourless oil. 12 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiazole-4-carboxamide 24
€
The general procedure was followed using 1,3-thiazole-4-carboxylic acid (4.40 mg, 34.2 µmol).
Purification by flash column chromatography (75% EtOAc/Hexane) provided amide 24 (9.8 mg, 82%), as a colourless oil. 13 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)oxazole-4-carboxamide 25
The general procedure was followed using 1, 14 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-2-methyloxazole-4-carboxamide 26
The general procedure was followed using 2-methyl- 15 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1-methyl-1H-pyrazole-5carboxamide 27
The general procedure was followed at a different scale. 16 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-5-methylfuran-2-carboxamide 28
The general procedure was followed using 5-methyl-furan-2-carboxylic acid (4.30 mg, 34.2 µmol).
Purification by flash column chromatography (75% EtOAc/Hexane) provided amide 28 ( 
N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-3-methylfuran-2-carboxamide 29
The general procedure was followed using 3-methyl-furan-2-carboxylic acid (4.30 mg, 34.2 µmol).
Purification by flash column chromatography (50% EtOAc/Hexane) provided amide 29 ( 18 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3- 
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-4,5-dimethylfuran-2-carboxamide 30
The general procedure was followed using 4,5-dimethylfuran-2-carboxylic acid (4.80 mg, 34.2 µmol).
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 30 ( 19 N-(6-(4-((2S,6S)-6-((4-((2S,6S) 
-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-5-chlorofuran-2-carboxamide 31
The general procedure was followed using 5-chlorofuran-2-carboxylic acid (5.00 mg, 34.2 µmol).
Purification by flash column chromatography (45% EtOAc/Hexane) provided amide 31 ( 
N-(6-methoxyhexyl)-5-nitrofuran-2-carboxamide 35
To a solution of N-(6-hydroxyhexyl)-5-nitrofuran-2-carboxamide S11 (9.70 mg, 37.9 µmol) and 1,8- 
Biological Testing
Cell culture
Bloodstream form T. brucei brucei strain 427 were grown in HMI-9 media supplemented with 10% foetal bovine serum (Gibco) and 2.5 µg/mL G418 (Calbiochem) at 37°C with 5% v/v CO 2 with 10% bovine serum and G418 (2.5 µg/mL) at 37°C with 5% v/v CO 2 , as described elsewhere . HeLa cells (ATCC® CCL-2) and African Green monkey kidney Vero cells (ECACC 84113001) were cultured in Dulbecco's Modified Eagle Medium (DMEM, Sigma) supplemented with 10% foetal bovine serum and grown at 37 °C in 5% CO 2 atmosphere.
Epimastigote Trypanosoma cruzi CL Brener strain were grown at 28 °C in RPMI 1640 medium (Sigma) supplemented with 20 mM HEPES pH 7.2 (Sigma), 4.9 mg/mL tryptone (Sigma), PGAB (2 mM sodium glutamate, 2 mM sodium pyruvate, 100 µg/mL streptomycin and 100 U/mL penicillin, all Sigma), 20 µg/mL haemin and 10% heat-inactivated foetal bovine serum.
Promastigote L. major MHOM/IL/80/Friedlin were grown at 28 °C in M199 media (Sigma) pH 7.4, supplemented with 40 mM HEPES pH 7.4, 100 µM adenosine, 5 µg/mL haemin and 10% heatinactivated foetal bovine serum.
Cytotoxicity assays
The determination of the EC 50 of the compounds using Alamar Blue was completed as previously described. 29 Briefly, compounds were made up in DMSO and two-fold serial dilutions of compound in media were carried out in a 96-well plate in quadruplicate. Cells were counted using CASY Cell
Counter and seeded as specified below.
Bloodstream form parasites, procyclic form parasites and HeLa cells were plated out at 1x10 3 cells/well, 1x10 4 cells/well and 1x10 3 cells/well, respectively. After 64 hours (3 days) Alamar Blue was added to each well and left for 6-8 hours to develop.
Mid-log L. major were diluted in media and seeded at 2 x10 5 per well in 100 µL media. Negative controls of DMSO only were included. Plates were incubated at 28 °C for 72 hours, after which 20 µL Alamar Blue (12.5 mg resazurin salt in 100 mL PBS) was added to all wells and incubated for a further 6 hours.
Mid-log T. cruzi were diluted in media and seeded at 5 x10 5 per well in 100 µL media. Negative controls of DMSO only and positive control of nifurtimox were included. Plates were incubated at 28 °C for 72 hours, after which 10 µL Alamar Blue was added to all wells and incubated for a further 6
hours.
For Vero cell assays, the monolayer was trypsinized, diluted in media and cells were seeded at 4 x10 3 cells per well. Cells were incubated at 37 °C with 5% CO 2 for 24 hours to allow attachment, after which media was removed and replaced with fresh media containing serial dilutions of compound. Drug diluted in media was added and plates were incubated for 72 hours, after which 10 µL Alamar Blue was added to all wells and incubated for a further 2 hours.
Cell viability was quantified using an FLx 800 plate reader (BioTek) with excitation wavelength 540/35 nm and emission wavelength at 590/10 nm using Gen5 Reader Control 2.0 Software (BioTek). EC 50 values were determined using a 4-parameter logistic regression equation using GraFit 5.0 (Erithacus Software).
